These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34049985)

  • 1.
    Zhang Y; Kupferschlaeger J; Lang P; Reischl G; Handgretinger RJ; Fougère C; Dittmann H
    J Nucl Med; 2022 Feb; 63(2):205-211. PubMed ID: 34049985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and Dosimetry of
    Pandit-Taskar N; Zanzonico P; Staton KD; Carrasquillo JA; Reidy-Lagunes D; Lyashchenko S; Burnazi E; Zhang H; Lewis JS; Blasberg R; Larson SM; Weber WA; Modak S
    J Nucl Med; 2018 Jan; 59(1):147-153. PubMed ID: 28705916
    [No Abstract]   [Full Text] [Related]  

  • 4. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
    Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
    Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
    [No Abstract]   [Full Text] [Related]  

  • 6. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
    Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM
    Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
    Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
    J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
    Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-dosing with lilotomab prior to therapy with
    Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.
    Kramer K; Humm JL; Souweidane MM; Zanzonico PB; Dunkel IJ; Gerald WL; Khakoo Y; Yeh SD; Yeung HW; Finn RD; Wolden SL; Larson SM; Cheung NK
    J Clin Oncol; 2007 Dec; 25(34):5465-70. PubMed ID: 18048828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and Radiation Dosimetry of Intraperitoneally Administered
    Grkovski M; Modak S; Zanzonico PB; Carrasquillo JA; Larson SM; Humm JL; Pandit-Taskar N
    J Nucl Med; 2022 Jul; 63(7):1094-1100. PubMed ID: 34857661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
    Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
    Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
    J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
    Handgretinger R; Anderson K; Lang P; Dopfer R; Klingebiel T; Schrappe M; Reuland P; Gillies SD; Reisfeld RA; Neithammer D
    Eur J Cancer; 1995; 31A(2):261-7. PubMed ID: 7718335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
    Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
    Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
    J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.